Holen Sie sich die Stockscreener-App
25.28
0.23%
-0.0589
Schlusskurs vom Vortag:
$25.34
Offen:
$25.18
24-Stunden-Volumen:
1,386
Relative Volume:
0.98
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.25%
1M Leistung:
+1.84%
6M Leistung:
+5.67%
1J Leistung:
+6.05%
1-Tages-Spanne:
$25.18
$25.31
1-Wochen-Bereich:
$24.68
$25.40
52-Wochen-Spanne:
$18.56
$26.27
Amplify Weight Loss Drug Treatment Etf Stock (THNR) Company Profile
Firmenname
Amplify Weight Loss Drug Treatment Etf
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie THNR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
THNR
Amplify Weight Loss Drug Treatment Etf
|
25.28 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
335.99 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
681.76 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
685.17 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
262.61 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
613.62 | 124.43B | 0 | 0 | 0 | 0.00 |
Amplify Weight Loss Drug Treatment Etf Aktie (THNR) Neueste Nachrichten
Can You Buy Ozempic Stock in 2025? - The Motley Fool
2 Dividend ETFs to Avoid and 1 to Buy Right Now - AOL.com
Tema’s Oncology ETF (CANC) Surpasses $100m in Assets Amidst Strong 2025 Performance - PharmiWeb.com
ETFs Investing in JIANGSU HENGRUI PHARMACEUTICALS CO LTD Stocks - TradingView
Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in - sharewise.com
Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk - Benzinga
How (THNR) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Trading Systems Reacting to (THNR) Volatility - news.stocktradersdaily.com
3 Under-the-Radar Monthly Dividend ETFs - 24/7 Wall St.
SCHD Isn’t Your Only Option — 2 Monthly ETFs With Better Long-Term Gains - 24/7 Wall St.
The Investor's Guide to Buying GLP-1 Stocks - The Motley Fool
CF Acquisition Corp. VI (OTCMKTS:CFVIU) Trading Up 2.1% – Should You Buy? - Defense World
Elemental Altus Royalties (OTCMKTS:ELEMF) Trading Down 6.5% – Time to Sell? - Defense World
How Amplify Weight Loss Drug & Treatment Etf (THNR) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Defense Metals (CVE:DEFN) Trading Up 22.6% – Should You Buy? - Defense World
3 Monthly Dividend ETFs That Outperform SCHD and Pay You More Often - 24/7 Wall St.
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs - Benzinga
2 Elite Dividend ETFs That Yield Over 5% - 24/7 Wall St.
Eli Lilly's LLY Surges 4.38% on Groundbreaking Obesity Drug Data – What's Next for the Pharma Giant? - AInvest
Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers - Benzinga
NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain - Nasdaq
Novo Nordisk Surges 2.46% Amid Leadership Shift and Sector Volatility – What’s Fueling the Rally? - AInvest
Bank of America Issues Pessimistic Forecast for CAVA Group (NYSE:CAVA) Stock Price - Defense World
Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Short Interest Update - Defense World
Amgen Plummets 5.4% Amid MariTide Hype: Can This Biotech Giant Rebound? - AInvest
4 Super High-Yield Dividend Picks for Steady Passive Income - 24/7 Wall St.
Novo Nordisk Shares Plunge, Drag Down Weight-Loss-Drug ETFs - Yahoo Finance
3 Monthly-Paying Dividend ETFs Perfect for Retirement Income - 24/7 Wall St.
(THNR) On The My Stocks Page - news.stocktradersdaily.com
8 of the Safest High-Yielding ETFs That Will Protect Your Portfolio - 24/7 Wall St.
When (THNR) Moves Investors should Listen - news.stocktradersdaily.com
The 3 Best ETFs for Soaring Silver Prices - 24/7 Wall St.
(THNR) Proactive Strategies - news.stocktradersdaily.com
Weight-Loss Drug ETFs Generate Skinnier Returns Than Expected - Yahoo Finance
(THNR) Investment Analysis - news.stocktradersdaily.com
These 5 ETFs (QQQI, JEPQ, SCHD, DIVO, SPYI) Are Loved By Passive Income Seekers - 24/7 Wall St.
Weight Loss Drug ETF (THNR) Hits New 52-Week High - Yahoo
Investors Need To Buy This High-Yield, 11% ETF That Pays Cash Every Month - 24/7 Wall St.
ETF Spotlight: HIMZ on the Rise After Wegovy Hookup - ETF.com
The pharma war rocking global markets - ig.com
ETFs to Capitalize on the Novo Nordisk-Septerna Deal - Yahoo Finance
Amplify ETFs CEO Christian Magoon on the Past 2 Decades of ETFs - The Daily Upside
ETFs Tied to S&P 500 Top Performers Show Mixed Results - ETF.com
Why Weight-Loss Drugs Could Be Game-Changers for Your Investment Portfolio - Investopedia
Slower flows, small-cap woes, SEC nos! What to expect from ETFs in 2025 - Citywire
New Year's Resolutions: Lose Weight & Allocate to GLP-1 ETFs - ETF Trends
Amplify ETFs Achieves Landmark $10 Billion in Assets Under Management - GlobeNewswire
Eli Lilly Cuts Q4 Sales Forecast: ETFs to Buy on the Dip - Yahoo Finance
Disruptive Theme of the Week: 2024's Top Investment Themes & Trends - ETF Trends
Disruptive Theme of the Week: Breakthroughs in Medicine - ETF Trends
Best Crypto ETFs of November 2024 - AOL.com
Finanzdaten der Amplify Weight Loss Drug Treatment Etf-Aktie (THNR)
Es liegen keine Finanzdaten für Amplify Weight Loss Drug Treatment Etf (THNR) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):